Cargando…

Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis

BACKGROUND: A multi-dimensional model can be a useful tool for estimating the general impact of disease on the different sectors of the healthcare system. We chose the sexually transmitted disease syphilis for our model due to the good quality of reported data in Germany. METHODS: The model included...

Descripción completa

Detalles Bibliográficos
Autores principales: Šmit, Renata, Wojtalewicz, Nathalie, Vierbaum, Laura, Nourbakhsh, Farzin, Schellenberg, Ingo, Hunfeld, Klaus-Peter, Lohr, Benedikt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086961/
https://www.ncbi.nlm.nih.gov/pubmed/35558533
http://dx.doi.org/10.3389/fpubh.2022.883564
_version_ 1784704118031384576
author Šmit, Renata
Wojtalewicz, Nathalie
Vierbaum, Laura
Nourbakhsh, Farzin
Schellenberg, Ingo
Hunfeld, Klaus-Peter
Lohr, Benedikt
author_facet Šmit, Renata
Wojtalewicz, Nathalie
Vierbaum, Laura
Nourbakhsh, Farzin
Schellenberg, Ingo
Hunfeld, Klaus-Peter
Lohr, Benedikt
author_sort Šmit, Renata
collection PubMed
description BACKGROUND: A multi-dimensional model can be a useful tool for estimating the general impact of disease on the different sectors of the healthcare system. We chose the sexually transmitted disease syphilis for our model due to the good quality of reported data in Germany. METHODS: The model included gender- and age-stratified incident cases of syphilis (in- and outpatients) provided by a German statutory health insurance company, as well as seroprevalence data on syphilis in first-time blood donors. Age standardized rates were calculated based on the standard German population. The test quality was assessed by extrapolating the number of false-positive and false-negative results based on data from Europe-wide external quality assessment (EQA) schemes. The model analysis was validated with the reported cases and diagnosis-related group (DRG)-statistics from 2010 to 2012. The annual direct and indirect economic burden was estimated based on the outcomes of our model. RESULTS: The standardized results were slightly higher than the results reported between 2010 and 2012. This could be due to an underassessment of cases in Germany or due to limitations of the dataset. The number of estimated inpatients was predicted with an accuracy of 89.8 %. Results from EQA schemes indicated an average sensitivity of 92.8 % and an average specificity of 99.9 % for the recommended sequential testing for syphilis. Based on our model, we estimated a total average minimal annual burden of €20,292,110 for syphilis on the German healthcare system between 2010 and 2012. CONCLUSIONS: The linking of claims data, results from EQA schemes, and blood donor surveillance can be a useful tool for assessing the burden of disease on the healthcare system. It can help raise awareness in populations potentially at risk for infectious diseases, demonstrate the need to educate potential risk groups, and may help with predictive cost calculations and planning.
format Online
Article
Text
id pubmed-9086961
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90869612022-05-11 Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis Šmit, Renata Wojtalewicz, Nathalie Vierbaum, Laura Nourbakhsh, Farzin Schellenberg, Ingo Hunfeld, Klaus-Peter Lohr, Benedikt Front Public Health Public Health BACKGROUND: A multi-dimensional model can be a useful tool for estimating the general impact of disease on the different sectors of the healthcare system. We chose the sexually transmitted disease syphilis for our model due to the good quality of reported data in Germany. METHODS: The model included gender- and age-stratified incident cases of syphilis (in- and outpatients) provided by a German statutory health insurance company, as well as seroprevalence data on syphilis in first-time blood donors. Age standardized rates were calculated based on the standard German population. The test quality was assessed by extrapolating the number of false-positive and false-negative results based on data from Europe-wide external quality assessment (EQA) schemes. The model analysis was validated with the reported cases and diagnosis-related group (DRG)-statistics from 2010 to 2012. The annual direct and indirect economic burden was estimated based on the outcomes of our model. RESULTS: The standardized results were slightly higher than the results reported between 2010 and 2012. This could be due to an underassessment of cases in Germany or due to limitations of the dataset. The number of estimated inpatients was predicted with an accuracy of 89.8 %. Results from EQA schemes indicated an average sensitivity of 92.8 % and an average specificity of 99.9 % for the recommended sequential testing for syphilis. Based on our model, we estimated a total average minimal annual burden of €20,292,110 for syphilis on the German healthcare system between 2010 and 2012. CONCLUSIONS: The linking of claims data, results from EQA schemes, and blood donor surveillance can be a useful tool for assessing the burden of disease on the healthcare system. It can help raise awareness in populations potentially at risk for infectious diseases, demonstrate the need to educate potential risk groups, and may help with predictive cost calculations and planning. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086961/ /pubmed/35558533 http://dx.doi.org/10.3389/fpubh.2022.883564 Text en Copyright © 2022 Šmit, Wojtalewicz, Vierbaum, Nourbakhsh, Schellenberg, Hunfeld and Lohr. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Šmit, Renata
Wojtalewicz, Nathalie
Vierbaum, Laura
Nourbakhsh, Farzin
Schellenberg, Ingo
Hunfeld, Klaus-Peter
Lohr, Benedikt
Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title_full Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title_fullStr Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title_full_unstemmed Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title_short Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis
title_sort epidemiology, management, quality of testing and cost of syphilis in germany: a retrospective model analysis
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086961/
https://www.ncbi.nlm.nih.gov/pubmed/35558533
http://dx.doi.org/10.3389/fpubh.2022.883564
work_keys_str_mv AT smitrenata epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT wojtalewicznathalie epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT vierbaumlaura epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT nourbakhshfarzin epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT schellenbergingo epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT hunfeldklauspeter epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis
AT lohrbenedikt epidemiologymanagementqualityoftestingandcostofsyphilisingermanyaretrospectivemodelanalysis